![]() | Up a level |
2017
De Castro, Gilberto, Jr., Tan, Daniel Shao-Weng, Crino, Lucio, Wu, Yi Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximilian, Cortot, Alexis, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario Garcia, Branle, Fabrice, Sen, Paramita, Mcculloch, Tracey and Soria, Jean-Charles (2017). First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). J. Thorac. Oncol., 12 (1). S. S7 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Tan, Daniel Shao-Weng, Soria, Jean-Charles, De Castro, Gilberto, Jr., Wu, Yi Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximilian, Cortot, Alexis, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario Garcia, Branle, Fabrice, Sen, Paramita, Struebbe, Gero, Mcculloch, Tracey and Crino, Lucio (2017). PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4). J. Thorac. Oncol., 12 (1). S. S1176 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380